



LA HEALTH-SYSTEM PHARMACIST

Newsletter of the Louisiana Society of Health-System Pharmacists

Editor: Dana Jamero djamero@xula.edu

www.lshp.org

Volume 21, No.4

September/October 2011

FROM THE DESK OF THE PRESIDENT

I would like to start by congratulating our new officers who were elected this month to the Board of Directors. Roxie Stewart will be our President-Elect. Brice Mohundro and Jessica Brady will serve as Board of Directors-Elect. We look forward to working with you, and thank you for your service to the organization. On August 13th and 14th, our Board of Directors met for our annual strategic planning meeting in Alexandria. The meeting was well attended and very productive. Thank you to those who attended for taking time out of your busy schedules. Here are a few of the highlights from our meeting:

- A committee was established to coordinate activities for the ASHP meeting in New Orleans in December.
- A motion was passed to allow for the chair of the Technician Activities Committee to be a voting member of the Board of Directors. This will be voted on by the general membership next May.
- A need for an update to our website and Facebook pages was discussed in great detail. Plans are being made for a new webpage. The office has changed our Facebook page and has sent requests to members.
- Our organization would also like to get involved in the push to prevent drug shortages. We plan to post shortage information on our website. Our committee on Pharmacy Management in coordination with our Drug Information Centers is working on this issue.

An emphasis this year has been placed on getting our committees more involved. I have contacted members who have expressed interest in helping in this area, and have gotten nothing but positive results. Each committee has been assigned “charges” to complete over the year. In addition, the resolutions presented at the annual meeting have been assigned as follows:

- LSHP to contribute to the ASHP Research and Education Foundation for the ASHP Midyear Clinical

Meeting to be held in New Orleans. (Committee on Organizational Affairs & Documents).

- LSHP to develop a plan to help members implement the ASHP PPMI (Pharmacy Practice Model Initiative). (Committee on Education & Workforce Development)
- LSHP to help directors of pharmacy work together to prevent drug shortages and prevent wholesale fraud. (Committee on Pharmacy Management)
- LSHP to develop a position or statement regarding pushing wholesale drug companies. (Committee on Pharmacy Management)

Part of our ACPE accreditation process involves all programs being reviewed to make sure they meet requirements. An invitation has been sent to the membership asking for volunteers. Please consider this opportunity. This insures that as an organization we can continue to provide CE to our members.

Our Mid-Year meeting is fast approaching. It will be held again at Sam’s Town in Shreveport, La, on October 8th. Please join us on Friday the 7th for our welcome reception and check out the Red River Revel. Eleven CE hours will be presented, with a maximum of seven hours available per individual. Brochures should be our shortly, and we hope to see you there.

Finally, I want to remind everyone about the Mid-Year ASHP Clinical Meeting in New Orleans. LSHP has been busy making preparations. We hope that everyone will be able to attend at some point.

Sincerely,
Scott Dantonio, R.Ph.
LSHP President



INSIDE

Southeast LSHP Chapter update.....	3	LSHP Mid Year Meeting Information.....	5
Southwest LSHP Chapter update.....	3	LSHP Mid Year Meeting Schedule.....	6
Northeast LSHP Chapter update.....	3	LSHP Mid Year Meeting Registration Form.....	7
Role of Rosiglitazone (Avandia®) in Elevating Cardiovascular Risk in Patients with Diabetes.....	3		

**LOUISIANA SOCIETY
OF HEALTH-SYSTEM PHARMACISTS
2011-12 BOARD OF DIRECTORS**

PRESIDENT

Scott Dantonio, RPh
Prairieville
(985) 651-1574
sdantonio3@eatel.net

PRESIDENT-ELECT

Roxie Stewart, PharmD.
Monroe
(318) 342-1703
rstewart@ulm.edu

PAST PRESIDENT

Teresa Nash, PharmD
New Orleans
(504) 842-3119
tnash@ochsner.org

SECRETARY

**Michael Cockerham, MS, PharmD,
BCOP**
Shreveport
(318) 632-2007
mcocke@lsuhsc.edu

TREASURER

Tommy Mannino, RPh
Baton Rouge
(225) 765-8441
tommann40@aol.com

MEMBER AT LARGE

Laurel Andrews, PharmD
Monroe
(318) 644-9375
landrews@ulm.edu

MEMBER AT LARGE

Michael Loftin, RPh
Shreveport
(318) 965-0820
arcicon@aol.com

MEMBER AT LARGE

Camtu Ho, PharmD
New Orleans
(504) 436-1790
cnho@xula.edu

DIRECTOR-ELECT

Brice Mohundro, PharmD
Baton Rouge
(225) 219-9793
Labruzzo@ulm.edu

MEMBER AT LARGE

Helen Calmes, PharmD
New Orleans
(504) 891-6774
hcalmes@chnola.org

DIRECTOR-ELECT

Jessica Brady, PharmD
Monroe
(318) 342-1697
brady@ulm.edu

CENTRAL-LSHP

Kelly Beurlet
(318) 445-3453
kkbeurlet@bellsouth.net

SOUTH CENTRAL-LSHP

Brice Mohundro, PharmD
(225) 219-9793
Labruzzo@ulm.edu

NORTH-LSHP

Jeri Latham, RPh, MBA
(318) 212-3327
jlatham@wkhs.com

SOUTHEAST-LSHP

Lovie Lewis, PharmD
(985) 215-3394
lflewis@xula.edu

NORTHEAST-LSHP

Jessica Brady, PharmD
(318) 342-1697
brady@ulm.edu

SOUTHWEST-LSHP

Ty Ledet
(337) 235-7242
Tyronne.ledet@earthhospitalaf.net

Congratulations to the new LSHP board members!

President-Elect:

Roxie Stewart, PharmD.

Assistant Professor, Pharmacy
Practice

University of Louisiana at Monroe
College of Pharmacy

Board of Directors-Elect:

Brice Mohundro, PharmD.

Assistant Professor, PharmD
University of Louisiana at
Monroe College of Pharmacy

**Jessica Helmer Brady, Pharm.D.,
BCPS**

Clinical Assistant Professor
University of Louisiana at Monroe
College of Pharmacy

LSHP Bimonthly Newsletter**LA HEALTH-SYSTEM PHARMACISTS****Publisher Information**

The *LA Health-System Pharmacist* is published 6 times a year by the LSHP, 8550 United Plaza Blvd., Suite 1001, Baton Rouge, LA 70809. Subscription to the *LA Health-System Pharmacist* is a benefit of LSHP membership. All articles published represent the opinions of the authors and do not reflect the policy of the LSHP unless so specified. *All student submissions must be reviewed by a pharmacist mentor whose name will be included on the article.*

Copy, advertising and nonmember subscription inquiries should be directed to the Copy Editor, Heather Gremillion, at (225) 922-4520. Advertising rate sheets and deadlines are available upon request.

Please send article submissions to the newsletter editor, Dana Jamero, via email at djamero@xula.edu.

Southeast LSHP Chapter Update

By Lovie Lewis, Chapter President

As we approach the end of 2011, I would like to thank all of our members for their continued support. The success of our chapter is dependent on its leadership and strategic planning. Our goal is to provide quality and informational dinner meetings in order to meet the needs of our members. The chapter has held six dinner meetings. Three were held at Xavier University and the remaining meetings were sponsored by pharmaceutical companies. Some of the topics that were covered include: Antibiotic Stewardship, STD Guidelines Update, and Clinical Treatment of *C. difficile*. We are extremely grateful to our company sponsors including American Regent, Otsuka, and Cubist. I would also like to take the opportunity to thank our speakers: Nakia Beard Pharm.D., Rebecca Castner Pharm.D, Camtu Ho

Pharm.D., Sara Al-Dahir Pharm.D., Hector Ventura, M.D., and Tomas Villanueva, D.O.

We are currently accepting nominations for President-Elect and Secretary/Treasurer. Dale Boudreaux, Assistant Director of Pharmacy at Ochsner Medical Center, will be our chapter president for 2012. Dale has been very instrumental in finding partners for our sponsored dinners. As president of SELSHP, I have had the wonderful opportunity of working with Heather Olivier, Secretary/Treasurer. She has been a tremendous help with planning the meetings.

We hope to see everyone in December for the 2011 ASHP Midyear Meeting. We are already working on meetings for the spring. We encourage you to send in your renewal forms and we look forward to seeing you in 2012.

Southwest LSHP Chapter Update

By Ty Ledet, Chapter President

SWLSHP had our first official business meeting on July 28, 2011 sponsored by Astella Pharmaceuticals. Sixteen members attended. Richard Ponder, MBA, CMRP, CPP, CEPP, CPhT spoke on the topic of integrating technician involvement into pharmacy workflow and involvement in professional societies. In addition, the officers were introduced, bylaw recommendations and adding a technician para-

graph to the by-laws indicating their fee structure and membership role were discussed and the new LSHP Chapter Map was presented showing the new parishes now included in the SW region. The new parishes include St. Landry, Lafayette, St. Martin, St. Mary, and Iberia. This caused an increase of 20 members moving to the SWLSHP Chapter FROM the SCLSHP Chapter, bringing the total membership to 31.

Northeast LSHP Chapter Update

By Jessica Brady, Chapter President

The Northeast Chapter has several fall meetings planned jointly with the 5th District Pharmacists Association including programs covering "COPD Awareness" with Richard Kearley, M.D., Pulmonology, sponsored by GlaxoSmith-Kline on September 15th; "Appropriate Medication Use in the Elderly", presented by Laurel Andrews, Pharm.D. on October 20th; and J. David Hayes, Pharm.D., will present "The Role of Insulin Analogs in T2DM" on November 17th, sponsored by

NovoNordisk. We welcome our new members and hope to see increased attendance at all meetings. NELSHP also congratulates two members on their recent LSHP elections-Roxie Stewart, President-elect and Jessica Brady, Board-member elect as well as our ULM Student LSHP Chapter for continued recognition as an ASHP Student Society of Health-System Pharmacists.

Role of Rosiglitazone (Avandia®) in Elevating Cardiovascular Risk in Patients with Diabetes

By Brooke Stein, PharmD Candidate

Rosiglitazone (Avandia®) is a type 2 diabetes mellitus (T2DM) agent from the thiazolidinedione (TZD) class. Antihyperglycemic agents in this class help to control high blood glucose levels by increasing insulin sensitivity of the target cells.¹ Rosiglitazone and pioglitazone are the two peroxisome proliferator-activated receptor gamma (PPAR γ) agonists in the thiazolidinedione class. These receptors are found to have several metabolic effects, and perhaps cardiovascular effects. When PPAR γ is

stimulated by TZDs, fluid retention occurs causing the patient to experience weight gain and edema.¹ This is of particular concern to researchers and is associated with an increased risk of cardiovascular (CV) morbidity and mortality.²

Nissen and Wolski conducted a meta-analysis, published in 2007, to review the effects of rosiglitazone on myocardial infarction (MI) and all-cause mortality.⁸ The meta-analysis demonstrated an association between rosiglitazone and increase MI and death from CV related causes. In 2010,

Rosiglitazone continued from page 3.

the authors performed an updated meta-analysis further demonstrated an elevated risk for MI⁵. Out of 202 clinical trials reviewed, 56 were included in the meta-analysis update. A total of 35,531 patients were analyzed (19,509 assigned to rosiglitazone and 16,022 assigned to the comparator groups). It is important to note that many of the trials analyzed in this meta-analysis are unpublished and the numbers of outcomes resulting in these trials are relatively low; only 7 trials used in this study were published for public viewing⁵. Ultimately, the meta-analysis found that MI risk was significantly increased (28 to 39% of patients taking rosiglitazone) while there was no increase in CV or all-cause mortality. The authors concluded that there was an unfavorable benefit to risk ratio for prescribing rosiglitazone.⁵

Home et al.² conducted a randomized, open-label study to evaluate the long-term impact of rosiglitazone's fluid retention qualities on CV outcomes, and its long-term effects on glycemic control. The time to the first CV hospitalization or death was set as the primary endpoint. The aim of the study was to evaluate CV outcomes in regards to rosiglitazone and the non-rosiglitazone group. The study was conducted at 327 centers in Europe and Australasia for 6 years. Included in the study were 4,458 T2DM patients with an A1c of 7.1 to 9% who were taking the maximum tolerated dose of metformin or sulfonylurea alone. An A1c of less than or equal to 7% was targeted by randomizing patients to add-on rosiglitazone, metformin, or sulfonylurea. If the A1c continued to be at or above 8.5% then a third oral glucose agent was added to the rosiglitazone treatment group or insulin to the non-rosiglitazone groups. In addition, if the triple oral therapy continued to fail then insulin would be started for those patients.²

Another study example associated with rosiglitazone CV risks was a non-inferiority trial comparing rosiglitazone and sulfonylurea. Results showed combination therapy with rosiglitazone was non-inferior to combination therapy with metformin or a sulfonylurea. On the other hand, the occurrence of HF events was double (61 vs. 29) in the rosiglitazone group.⁶ Authors found that patients who show signs of HF should not be taking rosiglitazone.⁶

In conclusion, controversy over the use of rosiglitazone stems from the data of several clinical trials^{2,4,5,6,7} suggesting an elevated risk of having a heart attack in patients treated with TZD's for T2DM. In reaction to the data, on September 23, 2010, the FDA took action to restrict the use of these products.² The new restrictions on the prescribing of rosiglitazone are part of a Risk Evaluation and Mitigation Strategy (REMS) program, also known as the Avandia®-Rosiglitazone Medicines Access Program, consisting of a medication guide and newly developed restricted access and distribution program.³ The REMS is set in place to help patients who are successfully treated with the medication, and patients whom cannot control their diabetes with other medication. Some of these patients are also uninterested in beginning pioglitazone treatment as an

alternative.³

In order to accomplish these things, both the healthcare provider and patient must be enrolled in the REMS program before prescribing or taking the medication. Rosiglitazone products will also only be available through mail order certified pharmacies registered in the program starting on November 18, 2011.⁴ GlaxoSmithKline is responsible for carrying out a communication plan that involves informing pharmacies and healthcare providers of the new restrictions placed on their product. They will also make sure that healthcare providers who prescribe, and pharmacies that dispense rosiglitazone are certified in the REMS program. Distributors of rosiglitazone also have to be specially certified and educated on the product. A web-based database will keep track of all enrolled prescribers, patients, pharmacies, and distributors.⁴

More extensive clinical trials should have been performed prior to concluding this product is a strong hazard to the patients receiving them because the evidence presented is based on two meta-analyses. Despite this, patients started on this medication are already at a high risk of having cardiovascular events due to their diabetes diagnosis. In addition, increases in fluid retention have been associated with the drug, and it is contraindicated in patients with NYHA Class III/IV heart failure, further highlighting the CV risks. Therefore, the new REMS program set in place is an appropriate response in order to more closely monitor the drug and help to control the public's fears as a result of media coverage on the dangers of rosiglitazone.

References

1. Lexicomp Online. <https://online.lexi.com/crlsql/servlet/crlonline>. Accessed July 11, 2011.
2. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. *Diabetologia*. 2005; 48: 1726-1735.
3. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia®, Avandamet, and Avandaryl. FDA, US Food and Drug Administration. <http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm>. Updated: May 23, 2011. Accessed: July 10, 2011.
4. GlaxoSmithKline. Rosiglitazone Risk Evaluation and Mitigation Strategy (REMS). <http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm>. Updated: May 23, 2011. Accessed: July 10, 2011.
5. Nissen SE, Wolski K. Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. *Arch Intern Med*. 2010; 170(14): 1191-1201.
6. Komajda M, McMurray JJV, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. *European Heart Journal*. 2010; 31: 824-831.
7. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population cohort study. *BMJ*. 2009; 339:b2942
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*. 2007;356:2457-71.

LSHP 2011 Mid Year Meeting

October 8, 2011

Sam's Town, Shreveport, LA

Join us for the Friday Welcome Reception & Red River Revel!

Come join us for hors d'oeuvres and refreshments from 7:00-9:00 p.m. on Friday, October 7th. The Welcome Reception will be held at the Barnwell Garden & Art Center at 610 Clyde Fant Parkway. It is just a short five minute walk from the conference hotel, Sam's Town. The festivities will continue at the Red River Revel! Enjoy visiting with your friends and colleagues before heading out to the Red River Revel, the largest outdoor festival in North Louisiana! Wander around during the last weekend of the festival, sample Louisiana cuisine, view over 100 artists' creations, and hear the sounds of great live music! Additional information on the Revel can be obtained at www.redriverrevel.com.

Exhibit Program and Lunch

An outstanding exposition has been planned for the Mid Year Meeting, displaying the latest pharmaceutical developments, products, equipment and services available. The expo will provide an excellent opportunity for you to visit with your colleagues and local industry representatives on Saturday, October 8th from 11:00 a.m. to 12:00 p.m. Lunch will be served in the exhibit hall at noon.

Overall Meeting Objectives & Target Audience

To provide information and instruction on a variety of topics to enhance pharmacists' training and skills and to provide pharmacists, pharmacy technicians and pharmacy students with instruction on important drug therapy and general pharmacy topics, relevant to current pharmacy practice in Louisiana and the United States. Programs appropriate for pharmacists are indicated by a "P" suffix in the program number. Programs acceptable for pharmacy technicians are indicated by a "T" suffix in the program number.

Hotel Registration

The meeting will be held at Sam's Town, located at 315 Clyde Fant Parkway in Shreveport. Reservations may be made by calling Sam's Town at (877) 429-0711. Make your room reservations by September 19, 2011 to receive the discounted room block rate. Mention group code S10LAS when making your reservations.

Cancellation & Refunds

To receive a refund, confirmed registrations must be cancelled in writing. A \$15 administrative fee will be charged for all refunds. No refunds will be issued for requests faxed or postmarked after October 1, 2011.

Accreditation

The Louisiana Society of Health-System Pharmacists and the University of North Carolina Eshelman School of Pharmacy are accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of continuing pharmacy education.

A total of 11.5 contact hours (1.15 CEUs) are scheduled for Saturday's program, of which a maximum of 7 hours (0.7 CEUs) may be earned by an individual participant.



To receive credit for the continuing education activities provided by LSHP, registrants must attend programs designated for their credential. They must also complete a Continuing Education Credit Report, including the Program Evaluation, and submit onsite upon program completion; and pay all applicable LSHP fees. LSHP will mail validated Statements of Continuing Pharmacy Education to participants within one month after the meeting.

To receive credit for the continuing education activity provided by University of North Carolina Eshelman School of Pharmacy (Universal Activity Number 0046-9999-11-115-L01-P), pharmacists must attend the program and complete the evaluation form provided by UNC, including the request for credit, and return it to the UNC representative at the completion of the session. Credit statements will be mailed within 2-4 weeks to participants.

Sponsors

Special thanks to the following sponsor who has already committed to supporting the 2011 LSHP Mid Year Meeting:

MORRIS & DICKSON

Schedule - Saturday, October 8, 2011

7:45-8:00 a.m.

Welcome & Announcements

8:00-9:00 a.m.

What's that Smell? Oops, Too Late. Chemical Agents of Concern and Preparing to Respond

Mark Ryan, PharmD

0179-0000-11-041-L04-P / 0179-0000-11-041-L04-T

1 contact hour (0.1 CEU)

9:00-10:30 a.m.

Focus on Hyponatremia: Understanding and Treating the Most Common Electrolyte Disorder

J. Herbert Patterson, PharmD, FCCP

0046-9999-11-115-L01-P

1.5 contact hours (0.15 CEUs)

Co-sponsored by the University of North Carolina Eshelman School of Pharmacy and

Paradigm Medical Communications, LLC.

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

OR

9:00 - 10:00 a.m.

American Heart Association Atrial Fibrillation Guideline Medication Updates

Brittany Florczykowski, PharmD

0179-0000-11-032-L01-P / 0179-0000-11-032-L01-T

1 contact hour (0.1 CEU)

10:00 - 11:00 a.m.

Migraines: Acute Treatment with Triptans

Nick Watson, PharmD

0179-0000-11-033-L01-P / 0179-0000-11-033-L01-T

1 contact hour (0.1 CEU)

11:00 a.m.-12:00 p.m.

Exhibits

12:00-1:00 p.m.

Lunch with Exhibitors

1:00-2:00 p.m.

Advances in Contraception

Jessica Brady, PharmD

0179-0000-11-034-L01-P / 0179-0000-11-034-L01-T

1 contact hour (0.1 CEU)

OR

What's New With Cephalosporins

Chad Davis, PharmD

0179-0000-11-035-L01-P / 0179-0000-11-035-L01-T

1 contact hour (0.1 CEU)

2:00-3:00 p.m.

Tendinitis: A Disease of Overuse or an Overused Term

Amanda Ranzino, PharmD

0179-0000-11-036-L01-P / 0179-0000-11-036-L01-T

1 contact hour (0.1 CEU)

OR

Emerging Treatments for Relapse Metastatic Breast Cancer

Michelle Dupre, PharmD

0179-0000-11-037-L01-P / 0179-0000-11-037-L01-T

1 contact hour (0.1 CEU)

3:00-4:00 p.m.

Smoking Your Bath Salts

Kelsey Trimble, PharmD

0179-0000-11-038-L04-P

1 contact hour (0.1 CEU)

OR

Advancements in Multiple Sclerosis

Eging Lu, PharmD

0179-0000-11-039-L01-P / 0179-0000-11-039-L01-T

1 contact hour (0.1 CEU)

4:00-5:00 p.m.

Non-Opioid IV Analgesics for Post-Op Pain

Megyn Tiller, PharmD

0179-0000-11-040-L01-P / 0179-0000-11-040-L01-T

1 contact hour (0.1 CEU)

LSHP 2011 Mid Year Meeting Registration Form

Discount for early registration if postmarked by September 16, 2011

Name: _____ Badge Name: _____
 Institution/Affiliation: _____ Position/Job Title: _____
 Designation: ___ Pharm.D. ___ R.Ph. ___ Technician ___ Other _____
 Home Address: _____ City/State/Zip: _____
 Business Phone: _____ Email: _____

Registration: Mid Year Meeting registration includes admission to all of Saturday's CE activities, the exhibit hall and lunch on Saturday, course materials and admission for the registrant and one guest to the Welcome Reception on Friday, October 7.

*Lapsed members may have their membership renewed through December 31, 2011 by paying the non-member fee.
 *New members may join through December 31, 2011 by completing and submitting a membership form and paying one-half of the annual dues plus the member registration fee. Membership forms are available at www.lshp.org or by contacting the LSHP office.

LSHP Pharmacist Member	_____	\$70
Pharmacist Non-Member*	_____	\$150
LSHP Technician Member	_____	\$35
Technician Non-member*	_____	\$70
Pharmacy Resident	_____	\$70
Student	_____	\$15

Spouse/Guest Exhibit Lunch _____ \$20

Additional Welcome Reception guests, each _____ \$15

Registrants may bring one spouse/guest free, additional guests are \$15 per person. List names below

Additional late registration fee if postmarked after September 16, 2011 _____ \$10

Contribution for student sponsorship to attend the Mid Year Meeting (\$25, \$50, \$75, \$100) _____

TOTAL AMOUNT: _____

Welcome Reception

I will attend the reception on Friday, October 7.

I will bring a spouse/guest(s). Guest Name(s): _____

*Registrants may bring **one** spouse/guest to the reception at no charge. Additional guests may attend for \$15.00 per person; please check above option for additional guests.*

Reservations must be made for Friday evening's reception. Tickets will only be distributed to registrants who have pre-registered.

PAYMENT: ___ Check ___ Visa ___ MasterCard ___ American Express

Name on Card: _____ Credit Card No.: _____

Exp. Date: _____

Billing Address for Card (If different from above address): _____

Signature: _____

Make checks payable to LSHP or provide credit card information and mail or fax to

LSHP, 8550 United Plaza Blvd, Suite 1001, Baton Rouge, LA 70809

Phone (225) 922-4520 Fax (225) 408-4422 office@lshp.org

Please contact the LSHP office if you have a disability and need special assistance, or have special dietary needs.

ASHP is returning to New Orleans!

ASHP 2011 Mid Year Clinical Meeting
December 4-8, 2011
New Orleans, LA

Don't miss this exciting meeting as the Crescent City plays host to ASHP, the national organization of hospital and health-system pharmacists.

Visit www.ashp.org for more information!

Like LSHP on Facebook!

LSHP now has a Facebook page. Please log onto Facebook and search for "Louisiana Society of Health-System Pharmacists" and click "Like" on the top of the page!

facebook.

Mark your calendar!

2012 LSHP ANNUAL MEETING

HILTON RIVERSIDE

NEW ORLEANS, LA

MAY 24-26, 2012